Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)

NCT01082887 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT01082887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01082887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)
Lead sponsor
Nantes University Hospital
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2010
Completion date
October 31, 2012
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma